DE69816100D1 - Herstellung von membranrezeptoren mit extrazellulären baculovirus - Google Patents

Herstellung von membranrezeptoren mit extrazellulären baculovirus

Info

Publication number
DE69816100D1
DE69816100D1 DE69816100T DE69816100T DE69816100D1 DE 69816100 D1 DE69816100 D1 DE 69816100D1 DE 69816100 T DE69816100 T DE 69816100T DE 69816100 T DE69816100 T DE 69816100T DE 69816100 D1 DE69816100 D1 DE 69816100D1
Authority
DE
Germany
Prior art keywords
production
membrane receptors
extracellular baculovirus
baculovirus
extracellular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69816100T
Other languages
English (en)
Other versions
DE69816100T2 (de
Inventor
Michel Bouvier
Thomas Loisel
Stefano Marullo
Pierre Boulanger
Donny Strosberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite de Montreal
Centre National de la Recherche Scientifique CNRS
Original Assignee
Universite de Montreal
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite de Montreal, Centre National de la Recherche Scientifique CNRS filed Critical Universite de Montreal
Application granted granted Critical
Publication of DE69816100D1 publication Critical patent/DE69816100D1/de
Publication of DE69816100T2 publication Critical patent/DE69816100T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DE69816100T 1997-04-11 1998-04-10 Herstellung von membranrezeptoren mit extrazellulären baculovirus Expired - Fee Related DE69816100T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9704476A FR2761994B1 (fr) 1997-04-11 1997-04-11 Preparation de recepteurs membranaires a partir de baculovirus extracellulaires
FR9704476 1997-04-11
PCT/FR1998/000736 WO1998046777A1 (fr) 1997-04-11 1998-04-10 Preparation de recepteurs membranaires a partir de baculovirus extracellulaires

Publications (2)

Publication Number Publication Date
DE69816100D1 true DE69816100D1 (de) 2003-08-07
DE69816100T2 DE69816100T2 (de) 2004-05-13

Family

ID=9505801

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69816100T Expired - Fee Related DE69816100T2 (de) 1997-04-11 1998-04-10 Herstellung von membranrezeptoren mit extrazellulären baculovirus

Country Status (5)

Country Link
US (3) US6713278B1 (de)
EP (1) EP1015618B1 (de)
DE (1) DE69816100T2 (de)
FR (1) FR2761994B1 (de)
WO (1) WO1998046777A1 (de)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002030098A (ja) * 2000-07-17 2002-01-29 Institute Of Immunology Co Ltd バキュロウィルスの発芽ウイルスからウイルスエンベロープを回収する方法
WO2002023199A2 (en) * 2000-09-14 2002-03-21 Reverse Proteomics Research Institute Co., Ltd. Method, system, apparatus and device for discovering and preparing chemical compounds
JP4655388B2 (ja) * 2001-03-05 2011-03-23 富士レビオ株式会社 タンパク質の生産方法
US7070978B2 (en) 2001-06-20 2006-07-04 Toudai Tlo, Ltd. Method for expressing and purifying proteins using budded baculovirus
JP2003052370A (ja) * 2001-08-16 2003-02-25 Sentan Kagaku Gijutsu Incubation Center:Kk 発芽バキュロウィルスを用いた機能を有する膜型受容体蛋白質の発現法
US20050004227A1 (en) * 2001-10-16 2005-01-06 Ryoichi Saitoh Cell growth inhibitor
EP1462113B1 (de) * 2001-12-04 2010-02-24 Chugai Seiyaku Kabushiki Kaisha ZELLWACHSTUMSHEMMER MIT ANTI-PepT-ANTIKÖRPER
WO2003083116A1 (fr) 2002-03-29 2003-10-09 Chugai Seiyaku Kabushiki Kaisha Procede de criblage d'inhibiteurs de transporteurs
WO2003104453A1 (ja) * 2002-06-05 2003-12-18 中外製薬株式会社 抗体作製方法
WO2004081048A1 (ja) 2003-03-13 2004-09-23 Chugai Seiyaku Kabushiki Kaisha 変異受容体に対するアゴニスト活性を有するリガンド
EP1621553A4 (de) * 2003-03-28 2006-08-23 Chugai Pharmaceutical Co Ltd Antikörper, die transportaktivität von peptidtransportern inhibieren
EP1642971B1 (de) 2003-06-18 2010-07-21 Chugai Seiyaku Kabushiki Kaisha Fucosetransporter
US7964767B2 (en) 2004-03-31 2011-06-21 Chugai Seiyaku Kabushiki Kaisha Transgenic mice expressing baculovirus soluble GP64 and methods of using such mice to make antibodies
EP1829961A4 (de) 2004-12-22 2008-06-04 Chugai Pharmaceutical Co Ltd Verfahren zur herstellung eines antikörpers unter verwendung einer zelle mit gehemmter fucosetransporterfunktion
WO2006106905A1 (ja) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha 会合制御によるポリペプチド製造方法
AU2006256041B2 (en) 2005-06-10 2012-03-29 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
EP2006381B1 (de) 2006-03-31 2016-02-03 Chugai Seiyaku Kabushiki Kaisha Verfahren zur kontrolle der blut-pharmakokinetik von antikörpern
CN105177091A (zh) 2006-03-31 2015-12-23 中外制药株式会社 用于纯化双特异性抗体的抗体修饰方法
EP2011870A4 (de) 2006-04-14 2010-09-15 Medical & Biol Lab Co Ltd Mutantes polypeptid mit effektorfunktion
JP5043008B2 (ja) 2006-06-08 2012-10-10 中外製薬株式会社 炎症性疾患の予防または治療剤
AR061986A1 (es) 2006-07-13 2008-08-10 Chugai Pharmaceutical Co Ltd Agentes inductores de muerte celular
US8025881B2 (en) 2006-07-21 2011-09-27 Chugai Seiyaku Kabushiki Kaisha BMP antibodies and methods of treating kidney disease using the same
CL2008000719A1 (es) 2007-03-12 2008-09-05 Univ Tokushima Chugai Seiyaku Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a
JP5117765B2 (ja) * 2007-05-28 2013-01-16 国立大学法人 東京大学 抗ｒｏｂｏ１抗体を含むｐｅｔ用腫瘍診断剤
EP4368721A2 (de) 2007-09-26 2024-05-15 Chugai Seiyaku Kabushiki Kaisha Verfahren zur modifizierung eines isoelektrischen punkts eines antikörpers durch aminosäuresubstitution in cdr
MX2010003158A (es) 2007-09-28 2010-04-14 Chugai Pharmaceutical Co Ltd Anticuerpo anti-glipicano-3 que tiene cinetica mejorada en plasma.
WO2009054435A1 (ja) 2007-10-24 2009-04-30 Otsuka Chemical Co., Ltd. 増強されたエフェクター機能を有するポリペプチド
CN101939424B (zh) 2007-12-05 2016-12-28 中外制药株式会社 抗nr10抗体及其应用
TWI441649B (zh) 2007-12-05 2014-06-21 Chugai Pharmaceutical Co Ltd Use of anti-NR10 monoclonal antibody with neutralizing activity against NR10 in the manufacture of prophylactic or therapeutic agents for pruritus
NO2708559T3 (de) 2008-04-11 2018-08-25
BRPI0910509B8 (pt) 2008-07-10 2021-05-25 Toray Industries uso do anticorpo, anticorpo e composição farmacêutica
KR101638490B1 (ko) 2008-08-05 2016-07-11 도레이 카부시키가이샤 암의 치료 및 예방용 의약 조성물
JP2010210772A (ja) 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
TW201118166A (en) 2009-09-24 2011-06-01 Chugai Pharmaceutical Co Ltd HLA class I-recognizing antibodies
EP2530109A4 (de) 2010-01-29 2013-08-28 Toray Industries Harzfolie auf polymilchsäurebasis
WO2011096519A1 (ja) 2010-02-04 2011-08-11 東レ株式会社 癌の治療及び／又は予防用医薬組成物
JP5906739B2 (ja) 2010-02-04 2016-04-20 東レ株式会社 癌の治療及び／又は予防用医薬組成物
MX340014B (es) 2010-02-04 2016-06-22 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
CA2788545C (en) 2010-02-04 2019-03-26 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
JP5742713B2 (ja) 2010-02-04 2015-07-01 東レ株式会社 癌の治療及び／又は予防用医薬組成物
EP2543388A4 (de) 2010-03-04 2013-11-27 Dainippon Sumitomo Pharma Co Arzneimittel für entzündliche darmerkrankungen
TWI667346B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的FcRn親和力之抗體
WO2011152503A1 (ja) 2010-06-02 2011-12-08 大日本住友製薬株式会社 自己免疫疾患またはアレルギー疾患の治療剤
PL2740798T3 (pl) 2011-08-04 2017-07-31 Toray Industries, Inc. Kompozycja leku do leczenia i/lub zapobiegania nowotworom
HUE039219T2 (hu) 2011-08-04 2018-12-28 Toray Industries Gyógyászati készítmény rák kezelésére és/vagy megelõzésére
JP6065591B2 (ja) 2011-08-04 2017-01-25 東レ株式会社 癌の治療及び／又は予防用医薬組成物
TW201817744A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
EP3939996A1 (de) 2011-09-30 2022-01-19 Chugai Seiyaku Kabushiki Kaisha Antigenbindende moleküle zur förderung der zersetzung von antigenen mit mehreren biologischen aktivitäten
US9638697B2 (en) 2011-10-03 2017-05-02 The University Of Tokyo Monoclonal antibody specifically recognizing asparagine synthetase
CN109134658B (zh) 2011-10-31 2022-10-14 中外制药株式会社 控制了重链与轻链的缔合的抗原结合分子
US9573993B2 (en) 2012-02-21 2017-02-21 Toray Industries, Inc. Pharmaceutical composition for treatment of cancer comprising an anti-CAPRIN-1 peptide antibody
JP6187255B2 (ja) 2012-02-21 2017-08-30 東レ株式会社 癌の治療及び／又は予防用医薬組成物
BR112014021103A2 (pt) 2012-02-21 2019-10-15 Toray Industries, Inc Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo
PT2818481T (pt) 2012-02-21 2019-10-25 Toray Industries Composição farmacêutica para tratamento e/ou prevenção de cancro
CA2869120C (en) 2012-03-30 2023-05-23 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of liver cancer
KR102052400B1 (ko) 2012-03-30 2019-12-06 도레이 카부시키가이샤 담낭암의 치료 및/또는 예방용 의약 조성물
EA031631B1 (ru) 2012-09-27 2019-01-31 Чугаи Сеияку Кабушики Каиша Способ лечения или предупреждения злокачественного новообразования, способ отбора пациента, способ тестирования предрасположенности к злокачественному новообразованию у субъекта, гибридный полипептид и его применения
PL3031826T3 (pl) 2013-08-09 2019-03-29 Toray Industries, Inc. Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi
RU2730594C2 (ru) 2013-09-27 2020-08-24 Чугаи Сейяку Кабусики Кайся Способ получения полипептидного гетеромультимера
EP3581179A1 (de) 2013-12-27 2019-12-18 Chugai Seiyaku Kabushiki Kaisha Mutantes fgfr-gatekeeper-gen und dagegen gerichteter wirkstoff
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
SG10201907215QA (en) 2015-02-05 2019-09-27 Chugai Pharmaceutical Co Ltd Antibodies Comprising An Ion Concentration Dependent Antigen-Binding Domain, Fc Region Variants, Il-8-Binding Antibodies, And Uses Therof
CR20180217A (es) 2015-09-18 2018-05-03 Chugai Pharmaceutical Co Ltd Anticuerpos que se unen a interleucina 8 (il-8) y sus usos
MX2018011109A (es) 2016-03-28 2018-11-09 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion de cancer.
MX2020008193A (es) 2018-02-09 2020-11-24 Nestle Skin Health Sa Nemolizumab en el tratamiento de dermatitis atópica con excoriación moderada a severa.
US11236157B2 (en) 2019-01-28 2022-02-01 Galderma Holding SA Treatment of skin lesions and pruritus in prurigo nodularis patients
TW202304510A (zh) 2021-04-07 2023-02-01 瑞士商葛德瑪控股公司 結節性癢疹之治療
EP4395657A1 (de) 2021-08-30 2024-07-10 Galderma Holding SA Behandlungen von atopischer dermatitis
TW202409083A (zh) 2022-05-02 2024-03-01 美商阿克思生物科學有限公司 抗-tigit抗體及其用途
US20240141050A1 (en) 2022-09-02 2024-05-02 Galderma Holding S.A. Treatments for prurigo nodularis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0349594A4 (en) * 1987-03-16 1990-09-26 American Biogenetic Sciences, Inc. Recombinant baculovirus occlusion bodies in vaccines and biological insecticides
CA2200835A1 (en) * 1994-09-23 1996-03-28 Frederick M. Boyce Use of a non-mammalian dna virus to express an exogenous gene in a mammalian cell
US6033903A (en) * 1995-06-02 2000-03-07 Applied Research Systems, ARS Holding N.V. Method of expressing and secreting soluble extracellular domains of human gonadotropin hormone receptors

Also Published As

Publication number Publication date
US6713278B1 (en) 2004-03-30
EP1015618A1 (de) 2000-07-05
US20060281150A1 (en) 2006-12-14
FR2761994B1 (fr) 1999-06-18
US7439030B2 (en) 2008-10-21
US7078189B2 (en) 2006-07-18
DE69816100T2 (de) 2004-05-13
WO1998046777A1 (fr) 1998-10-22
US20040142471A1 (en) 2004-07-22
FR2761994A1 (fr) 1998-10-16
EP1015618B1 (de) 2003-07-02

Similar Documents

Publication Publication Date Title
DE69816100D1 (de) Herstellung von membranrezeptoren mit extrazellulären baculovirus
DE59802696D1 (de) Herstellung von Carotinoiden
DE69830966D1 (de) Herstellung von Gummiartikeln
DK0969835T3 (da) Anvendelse af centrale cannabinoidreceptorantagonister til regulering af velsmag
DE69814249D1 (de) Herstellung von fluorierten Polymeren
DE69826015D1 (de) Herstellung von layered - superlattice - materialien unter ausschluss von sauerstoff
DE69812901D1 (de) Katalytische herstellung von pentafluorpropenen
DE69515097D1 (de) Hohlfaser Membran-Trockner mit interner Spülung
DE69937003D1 (de) Mit wasserabweisendem material beschichtete faser
DE69716123D1 (de) Netzwerkverwalter mit verbesserter verbindungstauglichkeit
DE69816670D1 (de) Herstellung von alkylaromaten
DE69827005D1 (de) Herstellung von waschmittelgranulaten
DE60118185D1 (de) Herstellung von polyarylenetherharzen mit hoher intrinsischer viskosität
TR199902592A3 (tr) Bükümlü sentetik liften halat.
DE69814388D1 (de) Herstellung von waschmittelgranulaten
DE69615473D1 (de) Kunsthaut unter Verwendung von Meeresorganismen
DE69620036D1 (de) Hohlfaser-filtrationsmembran
DE69827788D1 (de) Herstellung von hydroxyurethanen
DE69836875D1 (de) Membranelektrolyseur
DE69828130D1 (de) Hohlfasermembran-Oxygenator
TR199801002A3 (tr) Selülozik lifli materyallerin çapraz-baglantisi.
DE69801392D1 (de) Herstellung von Methylchlorid
DE69709003D1 (de) Herstellung von Bisphenol-A
DE69624959D1 (de) Herstellung von Pentafluorphenylverbindungen
ATE365805T1 (de) Herstellung von l(+)-lactat

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee